IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ObsEva SA Developed novel therapeutics for women's reproductive health and pregnancy.	Switzerland	OBSN
OCULAR THERAPEUTIX, INC Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.	United States of America	OCUL
Oculis Holding AG Clinical-stage biopharma developing non-invasive topical therapies for ophthalmic diseases.	United States of America	OCS
ODI Pharma AB Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.	Sweden	ODI
Olema Pharmaceuticals, Inc. A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.	United States of America	OLMA
OliX Pharmaceuticals, Inc. Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.	South Korea	226950
OMEROS CORP Develops first-in-class therapeutics for challenging diseases with unmet medical needs.	United States of America	OMER
ONCODESIGN Developing precision oncology solutions for resistant and metastatic cancers.	France	ALONC
Oncodesign Precision Medicine S.A Develops precision therapies & diagnostics for resistant and metastatic cancers.	France	ALOPM
Oncoinvent ASA Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.	Norway	OCIN